WO1999029338A1 - Fibrinolytic inhibitor for sealant - Google Patents
Fibrinolytic inhibitor for sealant Download PDFInfo
- Publication number
- WO1999029338A1 WO1999029338A1 PCT/US1998/026059 US9826059W WO9929338A1 WO 1999029338 A1 WO1999029338 A1 WO 1999029338A1 US 9826059 W US9826059 W US 9826059W WO 9929338 A1 WO9929338 A1 WO 9929338A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fibrin
- clot
- preparation
- fibrinolysis
- monomer
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims description 40
- 239000000565 sealant Substances 0.000 title claims description 32
- 230000003480 fibrinolytic effect Effects 0.000 title description 16
- 239000003527 fibrinolytic agent Substances 0.000 title description 15
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims abstract description 159
- 108010073385 Fibrin Proteins 0.000 claims abstract description 95
- 102000009123 Fibrin Human genes 0.000 claims abstract description 95
- 229950003499 fibrin Drugs 0.000 claims abstract description 95
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 63
- 108010073651 fibrinmonomer Proteins 0.000 claims abstract description 61
- 238000002360 preparation method Methods 0.000 claims abstract description 58
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 56
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 52
- 230000020764 fibrinolysis Effects 0.000 claims abstract description 48
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 19
- 230000000379 polymerizing effect Effects 0.000 claims abstract description 16
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 claims abstract description 11
- 230000000087 stabilizing effect Effects 0.000 claims abstract description 11
- 230000002255 enzymatic effect Effects 0.000 claims abstract description 8
- 230000027455 binding Effects 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 51
- 239000007787 solid Substances 0.000 claims description 49
- 102000004190 Enzymes Human genes 0.000 claims description 31
- 108090000790 Enzymes Proteins 0.000 claims description 31
- 239000003446 ligand Substances 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 28
- 229920000642 polymer Polymers 0.000 claims description 23
- 102000003801 alpha-2-Antiplasmin Human genes 0.000 claims description 20
- 108090000183 alpha-2-Antiplasmin Proteins 0.000 claims description 20
- 108010049003 Fibrinogen Proteins 0.000 claims description 17
- 102000008946 Fibrinogen Human genes 0.000 claims description 17
- 229940012952 fibrinogen Drugs 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 17
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 12
- 102000013566 Plasminogen Human genes 0.000 claims description 11
- 108010051456 Plasminogen Proteins 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 9
- 239000000178 monomer Substances 0.000 claims description 6
- 230000003381 solubilizing effect Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 239000012062 aqueous buffer Substances 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 208000031737 Tissue Adhesions Diseases 0.000 claims description 2
- 239000003914 blood derivative Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 description 29
- 210000002381 plasma Anatomy 0.000 description 21
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 229920001184 polypeptide Polymers 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 238000006116 polymerization reaction Methods 0.000 description 13
- 239000011343 solid material Substances 0.000 description 13
- 230000003993 interaction Effects 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 108010071289 Factor XIII Proteins 0.000 description 9
- 229940012444 factor xiii Drugs 0.000 description 9
- 108091005804 Peptidases Proteins 0.000 description 8
- 102000035195 Peptidases Human genes 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 229940012957 plasmin Drugs 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 229920000936 Agarose Polymers 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 108010039627 Aprotinin Proteins 0.000 description 5
- 108090001008 Avidin Proteins 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 5
- 108010090804 Streptavidin Proteins 0.000 description 5
- 229960004405 aprotinin Drugs 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 235000019833 protease Nutrition 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000035602 clotting Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 241000271506 Bothrops Species 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 235000003332 Ilex aquifolium Nutrition 0.000 description 2
- 241000209027 Ilex aquifolium Species 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- 102000002933 Thioredoxin Human genes 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000003196 chaotropic effect Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000000368 destabilizing effect Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- YUPQOCKHBKYZMN-UHFFFAOYSA-N ethylaminomethanetriol Chemical compound CCNC(O)(O)O YUPQOCKHBKYZMN-UHFFFAOYSA-N 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- -1 o-carboxyphenyl Chemical group 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000005932 reductive alkylation reaction Methods 0.000 description 2
- 239000003998 snake venom Substances 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 229940094937 thioredoxin Drugs 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- DSVOSLJAGTUKFB-SPAGYVKCSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]pentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1C(=O)CN DSVOSLJAGTUKFB-SPAGYVKCSA-N 0.000 description 1
- WNKKRLJRXMEVSB-UHFFFAOYSA-N 1-(cyclohexylamino)ethanesulfonic acid Chemical compound OS(=O)(=O)C(C)NC1CCCCC1 WNKKRLJRXMEVSB-UHFFFAOYSA-N 0.000 description 1
- DSXZIKVKQAFHAN-UHFFFAOYSA-N 1-morpholin-4-ylpropane-1-sulfonic acid Chemical compound CCC(S(O)(=O)=O)N1CCOCC1 DSXZIKVKQAFHAN-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- ZYVIIEFODRWQGD-UHFFFAOYSA-N 2-piperazin-1-ylethanol;propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O.OCCN1CCNCC1 ZYVIIEFODRWQGD-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 241000271039 Agkistrodon Species 0.000 description 1
- 241000271045 Agkistrodon contortrix contortrix Species 0.000 description 1
- 241000271946 Bitis gabonica Species 0.000 description 1
- 241000271508 Bothrops asper Species 0.000 description 1
- 241000271511 Bothrops atrox Species 0.000 description 1
- 241000271515 Bothrops insularis Species 0.000 description 1
- 241000271517 Bothrops jararaca Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000271581 Calloselasma Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 241000271527 Crotalus adamanteus Species 0.000 description 1
- 241000271533 Crotalus durissus terrificus Species 0.000 description 1
- 241001505404 Deinagkistrodon acutus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000271042 Gloydius halys Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 1
- 101000605403 Homo sapiens Plasminogen Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000271481 Lachesis muta muta Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 238000003452 antibody preparation method Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229940038879 chelated zinc Drugs 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical class C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- HXQVQGWHFRNKMS-UHFFFAOYSA-M ethylmercurithiosalicylic acid Chemical compound CC[Hg]SC1=CC=CC=C1C(O)=O HXQVQGWHFRNKMS-UHFFFAOYSA-M 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 108010053364 glycyl-prolyl-arginyl-valyl-valyl-glutamic acid Proteins 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- MJGFBOZCAJSGQW-UHFFFAOYSA-N mercury sodium Chemical class [Na].[Hg] MJGFBOZCAJSGQW-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- BQVCCPGCDUSGOE-UHFFFAOYSA-N phenylarsine oxide Chemical compound O=[As]C1=CC=CC=C1 BQVCCPGCDUSGOE-UHFFFAOYSA-N 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- BPSIOYPQMFLKFR-UHFFFAOYSA-N trimethoxy-[3-(oxiran-2-ylmethoxy)propyl]silane Chemical compound CO[Si](OC)(OC)CCCOCC1CO1 BPSIOYPQMFLKFR-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004572 zinc-binding Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
- A61L31/046—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/043—Mixtures of macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/106—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Definitions
- the present invention is directed to a fibrin sealant containing a fibrinolytic inhibitor, a method of isolating such a fibrinolytic inhibitor, and a device that isolates such a fibrinolytic inhibitor through an automated process utilizing centrifugal force
- Fibrin sealants are widely used to reduce bleeding in surgery and to seal blood vessels and tissues that have been dissected either in surgery or through wounding
- the term "fibrin” can be viewed as a misnomer in this context since historically "fibrin" sealants have been delivered as a material containing the precursor of fibrin, namely fibrinogen In such sealants, fibrinogen material has been co-delivered at the site to be sealed with a proteinase enzyme that converts the fibrinogen to fibrin Once a sufficient amount of fibrin is formed from the fibrinogen, the fibrin spontaneously polymerizes into a fibrin polymer which - when sufficient polymer is assembled - forms a fibrin clot
- the conversion enzyme has been bovine
- this fibrin monomer sealant of EP 592,242 is that the sealant can be rapidly prepared from a small amount of a patient's blood only minutes before surgery, and this can be done using standard laboratory equipment Processes for deriving the fibrinogen material of prior art sealants are much more demanding and more difficult to automate Specialized tools for preparing fibrin monomer have also recently been described, and these tools allow an autologous sealant to be prepared from a patient in a rapid, highly reproducible, highly reliable, and highly safe manner See, Holm, "Centrifuge Reagent Delivery System", WO 96/16713, Holm et al., "Method and Device for Separating Fibrin I from Blood Plasma", WO 96/16714 and Holm, "Centrifuge with Annular Filter", WO 96/16715 These patent applications describe a molded apparatus that operates in a centrifuge A first chamber of the apparatus is filled with blood, and a centrifugation process separates the plasma from a
- the fibrin precipitate is pelleted by centrifugation, and the remaining plasma is transferred back to the first chamber.
- the pelleted fibrin precipitate is dissolved with a solubilizing liquid, which is most often an aqueous solution buffered at an acidic pH.
- the viscous fibrin monomer solution is mixed with agarose beads having bound avidin to remove traces of biotinylated conversion enzyme, and then washed into a third chamber (for example, a syringe) through a filter which removes the agarose beads.
- the retained agarose contains any residual enzyme bound via the high-affinity avidin-biotin interaction.
- the solubilized fibrin monomer composition can be used as a sealant as described in Edwardson et al, EP 592,242.
- an autologous sealant to be prepared in a rapid, automated process, and the autologous sealant so prepared is free of extrinsic proteinase enzymes such as bovine thrombin.
- the sealant does not contain quantities of inhibitors against fibrinolysis. These inhibitors can limit the rate, after the sealant has been used to form a fibrin clot, at which the body's housekeeping enzymes remove clotted fibrin.
- Aprotinin a 6200 molecular weight polypeptide isolated from bovine lung, is one such fibrinolytic inhibitor.
- Bovine aprotinin could, of course, be added to the above-described sealant, but this would partially undermine one of the substantial advantages of the sealant, which advantage is the ability to prepare the sealant autologously so that the sealant and clot formed with the sealant contain only biopolymers that are derived from the patient.
- the repeated use in a patient of bovine aprotinin has been associated with adverse consequences such as hypersensitive reactions.
- a method of easily preparing from the species to be treated most preferably the patient him or herself, a suitable inhibitor of fibrinolysis.
- a suitable inhibitor of fibrinolysis In particular, what is needed is a method that can be coordinated with the automated process described above. Summary of the Invention
- the invention provides a kit for preparing a fibrin sealant, wherein the kit is a first kit (A) comprising: (a) a fibrin monomer preparation; (b) a stabilizing preparation containing a clot-preserving effective amount of a fibrinolysis-inhibiting protein; and (c) a non-enzymatic polymerizing agent preparation effective to convert the fibrin monomer preparation into a fibrin clot; or a second kit (B) comprising: (a') a fibrin monomer preparation comprising a fibrin monomer and a clot-preserving effective amount of a fibrinolysis-inhibiting protein; and (c ' ) a polymerizing agent preparation effective to convert the fibrin monomer preparation into a fibrin clot.
- A comprising: (a) a fibrin monomer preparation; (b) a stabilizing preparation containing a clot-preserving effective amount of a fibrinolysis-inhibiting protein; and (c) a non-enzymatic poly
- the fibrin-clot stabilizing effective amount is: (i) in a stabilizing preparation that is a solution, at least about 70 ⁇ g/ml alpha-2-antiplasmin, (more preferably 200 ⁇ g/ml, still more preferably 400 ⁇ g/ml); or (ii) in a stabilizing preparation that is a solid, at least about 70 mg alpha- 2-antiplasmin per g of fibrin, (more preferably 120 mg per g, still more preferably 30 mg per g.
- the fibrin monomer preparation is a liquid and the concentration of fibrin monomer in the preparation is at least about 8 mg/ml (more preferably 15 mg/ml, still more preferably 30 mg/ml).
- the fibrin monomer preparation comprises a fibrin-solubilizing effective amount of acid and the polymerizing agent preparation comprises an amount of base sufficient to bring the amount of acid to less than a fibrin- solubilizing effective amount or the fibrin monomer preparation comprises a fibrin monomer lyophilizate and the polymerizing agent preparation comprises an aqueous buffer.
- the invention also provides a method of forming a fibrin sealant from an animal comprising: (a) contacting a first extract from the animal containing a fibrinolysis- inhibiting protein with a clot inhibitor-binding ligand bound to an extraction implement; (b) isolating a first composition comprising a fibrinolysis-inhibiting protein; (c) contacting a second extract from the animal, which contains fibrinogen and which can be the same as the first extract, with a fibrinogen-converting enzyme; and (d) isolating a second composition comprising a clot-forming effective amount of fibrin monomer from the contacted second extract, wherein the amount of isolated fibrinolysis-inhibiting protein is sufficient to stabilize at least a clot-forming effective amount of the second composition.
- the first and second extracts are the same, and the first extract is blood or a blood derivative.
- the method can further comprise (1) sealing a tissue to prevent fluid loss or to prevent adhesions to the tissue or (2) coating a material to increase its biocompatibility by: (e) contacting the second composition with a polymerizing agent composition ef ⁇ ective to convert the fibrin monomer preparation into a fibrin clot; and (f) further contacting the second composition with a clot preserving effective amount of the first composition.
- Figure 1 shows an outline of a procedure for preparing a fibrin sealant containing an autologous fibrinolytic inhibitor, where the inhibitor is removed from the plasma prior to polymerizing fibrin.
- Figure 2 shows an outline of a procedure for preparing a fibrin sealant containing an autologous fibrinolytic inhibitor, where the inhibitor is removed from post- polymerization serum.
- Figure 3 shows an alternative procedure where the autologous fibrinolytic inhibitor in a serum or plasma is first bound to an affinity ligand in the solution phase.
- Extraction implement is a structure that facilitates the removal from solution of molecules bound thereto. Extraction implements include without limitation solids or larger molecules that can be removed by sedimentation or filtration (including ultrafiltration), members of binding pairs where the other member of a binding pair can be used to extract the first binding pair from a solution, and charged or magnetic particles that can be extracted using electrical or magnetic fields.
- fibrinogen i.e., desAA-fibrin
- fibrin II i.e., desAAdesBB fibrin
- des BB fibrin a number of derivatives of fibrinogen ⁇ e.g., fibrin I (i.e., desAA-fibrin), fibrin II (i.e., desAAdesBB fibrin) or des BB fibrin ⁇ that can polymerize to form a precipitate of fibrin polymer.
- the derivatives are created by cleaving the A or B fibrinopeptides from fibrinogen.
- An effective amount of clot-forming fibrin is that quantity or concentration (if in a liquid form) of a fibrin (for example fibrin monomer) which forms sufficient clot material to be of utilized as a fibrin sealant.
- O fibrin-clot-preserving effective amount is that quantity or concentration (if in a liquid form) of a fibrin (for example fibrin monomer) which forms sufficient clot material to be of utilized as a fibrin sealant.
- An effective amount of fibrinolytic inhibitor is that quantity of alpha-2-antiplasmin or other fibrinolysis-inhibiting protein which when added to fibrin increases the time that a fibrin clot remains in or on a tissue as an effective fibrin sealant.
- Fibrin monomer is fibrin that is held in soluble form and prevented from clotting, for instance by the presence of a polymerization inhibitor such as acidic pH or a chaotropic agent or by being kept in a form which prevents polymerization, such as a sufficiently dehydrated form or a frozen form.
- a polymerization inhibitor such as acidic pH or a chaotropic agent
- Another form of fibrin monomer is an engineered version of fibrin which will not self-polymerize, but will polymerize with another fibrin- related molecule such as fibrinogen.
- Such an engineered fibrin is described in Cederholm et al., "Recombinant Fibrin Chains, Fibrin and Fibrin-Homologs," PCT Application No. PCT/US95/05527, filed May 2, 1995.
- Fibrin molecules in the absence of conditions that prevent polymerization of fibrin monomer, interact noncovalently to form polymers, here termed "fibrin polymers", which - when sufficient mass is achieved - form a visible adherent precipitate with clot-like properties.
- fibrin polymers By the action of factor XIII a , fibrin polymer can be covalently crosslinked.
- fibrin polymer Prior to the crosslinking action of factor XIII a , fibrin polymer can be reversibly converted to fibrin monomer. Even when some initial such crosslinking has occurred, it is believed that fibrin polymer can be reversibly converted to fibrin monomer.
- a fibrinolysis-inhibiting protein is a polypeptide found in a mammalian body fluid, or a polypeptide derived from such a mammalian polypeptide, that when infused or otherwise incorporated into a fibrin clot increases the time that the fibrin clot - when in contact with a tissue having plasmin or plasminogen - remains effective in, for example, binding tissues together, limiting body fluid leakage, preventing tissue adhesions or increasing the biocompatibility of a material.
- fibrinolysis-inhibiting proteins include alpha- 2-antiplasmin, alpha-2-macroglobin and aprotinin.
- High affinity binding between a first substance and a second substance is binding of sufficient avidity to allow for the first or second substance to be used as an affinity ligand for the isolation of the other substance
- high affinity binding is reflected in an association constant of about 10 5 M “1 or more, preferably 10 6 M “! or more, yet more preferably 10 7 M "1 or more.
- fibrinogen After the conversion from fibrinogen to fibrin, the fibrin rapidly polymerizes through noncovalent interactions such as hydrogen bonds, ionic bonds, hydrophobic interactions and Van der Waals interactions
- the polymerized fibrin forms a clot
- the clot can mature through the formation of covalent crosslinks under the direction of the active form of factor XIII, which is a transglutaminase enzyme called factor XIII a
- factor plasmin Plasmin is formed, in a highly regulated process, from a precursor called plasminogen Blood contains inhibitors of plasmin, including alpha-2-macroglobulin and alpha-
- Alpha-2-antiplasmin is believed to be the primary inhibitor of plasmin in the blood See, Aoki et al, J. Clm. Invest. 60. 361, 1977, and Collen and Wiman, Blood 51 : 563-569, 1978
- the reaction between AP and plasmin occurs in two steps, with the first being a rapid, reversible interaction (rate constant of the order of 10 ⁇ mol sec), and the second being a slower intra-molecular rearrangement that results in the formation of a covalent bond between alpha-2-antiplasmin and plasmin (rate constant of the order of 10 ⁇ mol/sec).
- alpha-2-antiplasmin becomes covalently attached to fibrin via activity of the same enzyme, factor XIII a , that crosslinks fibrin polymer
- Application No. 592,242 is made up of fibrin that is prevented from polymerization, i.e., fibrin monomer. Most often this polymerization prevention is achieved by solubilizing the fibrin in an aqueous solution having pH of about 4 To form a clot that can be used in surgery to minimize body fluid loss or to bond tissues together, the polymerization prevention conditions are reversed, which results in the rapid formation of fibrin polymer precipitate Generally, polymerization prevention is reversed by neutralizing the acidity of the fibrin composition at the same time the composition is being sprayed onto the site where clot formation is intended.
- the fibrin composition described in European Patent Application No. 592,242 can usefully contain an inhibitor of plasmin driven fibrinolytic housekeeping functions, such as the inhibitors aprotinin, alpha- 2-antiplasmin or alpha-2-macroglobulin.
- an inhibitor of plasmin driven fibrinolytic housekeeping functions such as the inhibitors aprotinin, alpha- 2-antiplasmin or alpha-2-macroglobulin.
- Such inhibitors increase the residence time of the resulting clot when the sealant is applied to tissues with high fibrinolytic activity such as prostate.
- an inhibitor is preferably easily isolated from blood in a rapid method that would allow the sealant composition to have all of its active components derived from the patient to which the sealant will be applied.
- the method preferably should also be readily adaptable to an automated process such as is available through the apparatuses described in Holm, WO 96/16713, Holm et al., WO 96/16714 and Holm, WO 96/16715.
- the method should further isolate the fibrinolytic inhibitor in sufficient concentration to provide a useful fibrinolytic inhibitor function to the fibrin sealant.
- the present invention provides such a method, as described further in the Summary of the Invention and the text below.
- Alpha-2-antiplasmin binds to plasminogen, and particularly it binds to one or more of the so-called "Kringle” domains of plasminogen, which are binding domains found in a number of proteins involved in coagulation or fibrinolysis. These Kringle domains consist of approximately 80-amino acid sequences, each with three disulfide bonds in conserved locations. Hoover et al., Biochemistry 32: 10936-10943, 1993. These sequences can be used as the basis for procedures to identify other ligands that bind to alpha-2-antiplasmin, as described further below.
- AP-binding ligands can also be prepared by digesting plasminogen or plasmin with a proteinase, such as elastase or chymotrypsin, that can destroy plasmin's enzymatic activity, while preserving the alpha-2-antiplasmin-binding activity.
- a proteinase such as elastase or chymotrypsin
- Such proteinase digestion products can be used directly without purification, or a purification procedure can be applied to isolate fractions with binding activity.
- Additional AP-binding ligands can be identified by the methods described below or other protein chemistry or molecular biology techniques known to the art.
- Additional affinity ligands that can be used to isolate fibrinolysis-inhibiting proteins such as alpha-2 antiplasmin and alpha-2-macroglobin include appropriate monoclonal and polyclonal antibodies, dyes, and chelated zinc ions.
- Figure 1 outlines how ligands that bind fibrinolytic-inhibitors can be used to isolate fibrinolysis-inhibiting protein and particularly how to isolate such polypeptides together with fibrin monomer.
- blood is collected and a plasma is isolated therefrom.
- the blood can be mixed with an anticoagulant, such as trisodium citrate to a final concentration of about 0.5% w/v, and the plasma can be isolated by centrifugation, which removes the cellular components of the blood.
- a solid support having a bound ligand that binds to a fibrinolysis-inhibiting protein is mixed with the plasma to bind a fibrinolysis-inhibiting protein found in the plasma.
- the solid support is separated from the plasma.
- the solid support can be washed with a solution designed to remove macromolecules found in the fluid removed with the solid support or non- specifically bound to the solid support.
- the solid support can be washed with an aqueous buffer having a substantially neutral pH, such as a pH between about 6 and about 8, and an ionic strength between about 0.05 M and about 0.3 M. All or part of the washes (for example, the initial wash) can be mixed with the plasma, which is then further processed to isolate fibrin monomer.
- a substantially neutral pH such as a pH between about 6 and about 8
- an ionic strength between about 0.05 M and about 0.3 M.
- the conditions for associating the antibody and fibrinolysis-inhibiting protein will vary with the characteristics of the antibody. These characteristics can be identified through standard experimentation. Where polyclonals are utilized, dissociation conditions often can be low pH, such as a pH of about 2.5. If low pH is used, care is taken to minimize the time to which the fibrinolysis-inhibiting protein is exposed to the low pH. For dye binding, dissociation is typically effected with elevated ionic strength solutions. Zinc chelation is more applicable to the post-polymerization embodiment of Figure 2 (discussed below), since fibrinogen exhibits competing binding to zinc, which competing binding makes it preferably to use zinc binding after the serum is fibrin depleted.
- the solid support is then eluted using conditions, such as are described further below, for destabilizing the interaction between the ligand and the fibrinolysis-inhibiting protein
- the buffer can be exchanged for a buffer suitable for use as a fibrinolytic inhibitor of a fibrm sealant or suitable for processing by lyophi zation
- factor XIII a inhibitors such as heavy metals (such as mercury), thiomerosal ⁇ [(o-carboxyphenyl) thiojethyl mercury sodium salt ⁇ , inhibitory antibodies, or calcium chelators (since calcium is a necessary cofactor for the enzyme)
- Calcium chelators include, but are not limited to, EGTA (ethylenediaminetetra-acetic acid, ethylenglycolb ⁇ s-(2-am ⁇ noethylether)tetra-acet ⁇ c acid), and the like
- the converting enzyme is baxtroxobin used at a concentration of about 0 1 ⁇ g/ml to about 100 ⁇ g/ml, preferably
- the fibrinogen-converting enzyme is batroxobm ("Btx"), a proteinase from the snake venom of snakes of the genus
- Snake venom proteinases are particularly suitable, including without limitation the venom enzymes from Agkistrodon acutus, Agkistrodon contortrix contortrix, Agkistrodon halys pallets, Agkistrodon (Calloselasma) rhodostoma, Bothrops asper, Bothrops atrox, Bothrops insularis, Bothrops jararaca, Bothrops Moojem, Lachesis muta muta, Crotalus adamanteus, Crotalus durissus terrificus, Trimeresiirus flavorvindis, Tnmeresurus gramineus and Bitis gabonica
- the fibrinogen-converting enzyme is favorably coupled to a converting enzyme binding partner which will be used in an affinity procedure to reduce the concentration of the enzyme in a preparation
- the converting enzyme binding partner is biotin, a member of the biotin-avidin binding pair, a pair of molecules that bind with extremely high affinity
- An amino acid sequence for avidin is described in Dayhoff, Atlas of Protein Sequence, Vol 5, National Biomedical Research Foundation, Washington, DC, 1972 (see also, DeLange and Huang, J. Biol Chem. 246 698-709, 1971), and an amino acid sequence for Streptavidin is described in Argarana et al , Nucl. Acid Res.
- Nucleic acid sequences are available, for example, as follows (1) chicken mRNA for avidin, Gene Bank Ace No X05343, Gore et al , Nucl. Acid Res. 15 3595-3606, 1987, (2) chicken, strain White Leghorn gene for avidin, Gene Bank Ace. No L27818 (3) streptavidin from Strep, avidinu, Gene Bank Ace No. X03591, Argarana et al , Nucl. Acid Res.
- Avidin and Streptavidin are preferably used in a tetrameric form, although monomers can be used
- Other binding pairs that bind with high affinity include an antibody specific for a polypeptide or other molecule, any polypeptide to which an antibody is available or can be prepared, thioredoxin, which binds phenylarsine oxide (expression vectors include, for example, the thioredoxin fusion protein vector pTrxFus available from Invitrogen, Carlsbad, CA), poly-His sequences that bind to divalent cations such as nickel II (expression vectors include, for example, the pThioHis vectors A, B and C available from Invitrogen), glutathione-S-transferase vectors that bind to glutathione (vector for example available from Pharmacia Biotech, Piscataway, NJ)
- Methods of producing such antibodies are available to those of ordinary skill in light of the ample description herein of polypeptide expression systems and of known antibody production methods For
- the fibrin formed will polymerize into fibrin polymer, and thereby form a fibrin clot.
- the desired fraction from the plasma comprises a solid clot and a solid support to which a fibrinolysis-inhibiting protein is bound.
- the desired fraction is a solids fraction made up of fibrin polymer, which can include components which co-process with the fibrin polymer.
- the conditions by which the fibrinolysis-inhibiting protein is eluted can be applied prior to the formation of fibrin monomer from the solid clot.
- the fibrin monomer can be prepared first, though care must be taken in selecting conditions for forming fibrin monomer that preserve the clot stabilizing activity of the fibrinolysis- inhibiting protein. Such conditions will vary depending upon the fibrinolysis-inhibiting protein that is to be isolated.
- fibrinolysis-inhibiting protein is alpha-2- antiplasmin
- care is preferably taken to limit the time or degree of exposure to low pH.
- fibrin monomer is recovered from the fibrin clot and, if the solid support (with bound fibrinolysis-inhibiting protein) is present, the fibrinolysis- inhibiting protein is dissociated from the inhibitor-binding ligand bound to the solid support. Fibrin monomer is recovered by adding a solubilizing agent to the fibrin clot.
- solubilizing agents can include, for example, acid solutions such as aqueous solutions having pH of about 5 or less, or chaotropic agents, such as urea, sodium bromide, guanidine hydrochloride, potassium cyanide, potassium iodide or potassium bromide.
- the solubilizing agents can be used at near the minimum concentration effective to maintain fibrin monomer (i.e., and fibrin- solubilizing effective amount).
- a number of conditions for forming fibrin monomer are described in Edwardson et al., European Patent Application No. EP 592,242.
- a solid material having bound thereto a second binding partner which is the complementary binding partner to the converting enzyme binding partner, is then added the fibrin monomer preparation to bind any converting enzyme as may continue to be found in the preparation.
- the solids which, depending on the protocol used, can include (a) the solid material, (b) the solid support or (c) any residual fibrin clot material, is then removed, for instance by filtration or centrifugation.
- the processed material can, depending on the procedure, comprise (1) a preparation containing fibrin monomer and the fibrinolysis-inhibiting protein, (2) separate preparations containing fibrin monomer and the fibrinolysis-inhibiting protein or (3) a preparation of fibrinolysis-inhibiting protein.
- Such processed materials can be stored in liquid form, for instance at about 4°C or less, in frozen form, or as a dried form such as a lyophilizate. Lyophilizates are formed by standard methods. These lyophilizates are generally reconstituted in purified water or in a buffered aqueous solution.
- the same solution composition of solubilizing agent previously used in the process can be used to reconstitute the lyophilizate.
- an aqueous solution which either (a) lacks a solubilizing agent or (b) is capable of reversing any solubilizing conditions carried in the lyophilizate, is employed.
- a non- enzymatic polymerizing agent is any reagent effective to reverse the conditions that prevent the polymerization of fibrin monomer.
- the polymerizing agent can be a basic solution, such as, without limitation, a solution of HEPES (N-[2- hydroxyethyl)piperazine-N'-[ethanesulfonic acid]), sodium hydroxide, potassium hydroxide, calcium hydroxide, bicarbonate buffers such as sodium bicarbonate and potassium bicarbonate, tri-metal salts of citric acid, salts of acetic acid and salts of sulfuric acid.
- HEPES N-[2- hydroxyethyl)piperazine-N'-[ethanesulfonic acid]
- sodium hydroxide sodium hydroxide
- potassium hydroxide calcium hydroxide
- bicarbonate buffers such as sodium bicarbonate and potassium bicarbonate
- tri-metal salts of citric acid salts of acetic acid and salts of sulfuric acid.
- Preferred alkaline buffers include: carbonate/bicarbonate; glycine; bis hydroxeythylamino ethane sulphonic acid (BES); hydroxyethylpiperazine propane sulphonic acid (EPPS); Tricine; morpholino propane sulphonic acid (MOPS); trishydroxymethyl aminoethane sulphonic acid (TES); cyclohexylaminoethane sulphonic acid (CHES); trishydroxymethyl aminoethane sulphonic acid (TES)
- the amount of alkaline buffer that is utilized should be enough to allow polymerization of the fibrin It is preferred that about 10 parts to about one part of composition comprising fibrin monomer be mixed with about 1 part alkaline buffer It is even more preferred that such ratio be about 9.1 The preferred ratio depends on the buffer, its concentration and pH and the desired concentration of the fibrin polymer Where acidic pH is used as the solubilizing agent, preferably the fibrin solubilization occurs in the presence of calcium ions, such
- three streams of aqueous preparations are mixed to initiate a rapid clot formation process
- These preparations are the fibrin monomer preparation, the fibrinolysis-inhibiting protein, and the non-enzymatic polymerizing agent
- the sealant mixture is generally formed either during the process by which the sealant is applied to its recipient surface, or within a few minutes prior to application Generally, the sealant mixture remains conveniently pliable for about 30 seconds or less
- the three streams are sprayed so that they converge and mix Suitable spray heads are described in US Patent Nos 5,605,541, 5,376,079, and 5,520,658 and PCT Application 97/20585 2. Secondary binding protocols
- the fibrin clot inhibitor-binding ligand can have attached to it (1) a third binding partner or other which is a member of a high affinity binding pair, or (2) another extraction implement In this way, the fibrin clot inhibitor-binding ligand can be contacted with the plasma or serum under solution conditions, and then the fibrinolysis-inhibiting protein isolated for instance by contacting plasma or serum with a solid material to which is bound the other member of the high affinity binding pair (the fourth binding partner)
- Figure 3 illustrates such an embodiment which is analogous to that of Figure 2
- a fibrin clot inhibitor-binding ligand, to which a third binding partner is attached is added A solid material to which is attached the fourth binding partner is then used to remove the a fibrinolysis-inhibiting protein from the serum
- the serum is filtered through the solid material, though other forms of contacting are of course available.
- solid supports and solid materials The solid support or solid material to which inhibitor-binding ligands and second binding partners, respectively, are bound are most preferably particles of carbohydrate- based material such as agarose, cross-linked agarose or cross-linked dextran
- solid material is used herein to refer to the same types of solids as the term "solid support”, but the separate terms are used herein to accentuate the difference in the types of affinity ligands bound thereto
- the molecule to be bound to solid support or solid material will be a polypeptide, for which the most convenient functionality for covalent coupling is often an amino or thio moiety on the polypeptide
- Methods for covalently coupling molecules to solid supports or solid materials are well known in the art, and include for example creating reactive sites on the solid supports or solid materials with cyanogen bromide or reacting the solid supports or solid materials with bifunctional reagents such as diglycidyl ethers See, for example, "Attachment to Solid Supports" in
- Preferred solution conditions for associating the fibrinolysis-inhibiting protein with the solid support containing bound inhibitor-binding ligand include the use of an aqueous buffer, a substantially neutral pH.
- the temperature at which the fibrinolysis-inhibiting protein and the solid support are contacted is preferably between about 0°C and about 40°C. It is not necessary in the methods of the invention that all of the fibrinolysis- inhibiting protein in a starting material be associated with the solid support, however, it is desirable that a sufficient amount be associated to provide for clot stabilization.
- the plasma producing the fibrinolytic inhibitor is, in a preferred embodiment, about the same amount of plasma as used to produce the fibrin of the sealant.
- Useful reagents for destabilizing the interaction between the inhibitor-binding ligand bound to the solid support and the fibrinolysis-inhibiting protein include substances that compete for binding the fibrinolysis-inhibiting protein such as, for alpha-2- antiplasmin, AP-binding ligands that are not bound to the support, such as lysine, 6- aminohexanoic acid, and other lysine analogs.
- the elution solution can be 10 mM of such a lysine analog in the presence of an appropriate buffer and sufficient salt (such as 0.5 M NaCl) to minimize non-specific adsorptions to the solid support.
- the conditions that effect the dissociation of the fibrinolysis- inhibiting protein from the inhibitor-binding ligand bound to the solid support preferably allow the interaction between the converting enzyme binding partner and the second binding partner.
- the second binding partner, bound to the solid material can be used to remove residual converting enzyme without the need to (a) remove the solid support and (b) modify conditions to favor the interaction between the converting enzyme binding partner and the second binding partner.
- the Kringle regions of plasminogen serve as models for the design of alternative AP-binding ligands.
- the Kringle 1 region of human plasminogen corresponding to residues 84 through 162, is a particularly useful model.
- One design approach is the Multipin Synthetic Peptide System described by Beysen et al., J. Immunol. Methods 102: 259, 1987. Under this approach, for instance, numerous polypeptides having a relationship with one of the Kringle regions can be synthesized in a form attached via a polyethylene/polypropylene linkers to the surface of the wells of a microtiter plate.
- binding assays will typically include treatments of the solid surface to reduce non-specific binding, the use of polypeptides that are not related to a Kringle region to indicate the level of non-specific binding, and the use of established AP-binding ligands such as plasminogen to confirm that the assay is operative.
- phage display technology wherein recombinantly produced diversity libraries of polypeptides are presented on the surface of a phage, can be used.
- the phages selected for their ability to bind alpha-2- antiplasmin can be grown and the relevant portion of their genome sequenced to identify polypeptides with binding potential.
- Such phage display technology is described patent documents belonging to Dyax Corporation of Cambridge, Massachusetts, including Robert Ladner et al., U.S. Patent Nos. 5,223,409 (Directed Evolution of Novel Binding Proteins) and 5,403,484 (Viruses Expressing Chimeric Binding Proteins).
- the present invention can be used for treating any animal having a fibrin-based system for controlling bleeding, but is preferably used for treating mammals, most preferably humans
- Example 1 Preparation of Plasminogen Fragments and Attachment of AP-binding Ligands to Cross-linked Agarose
- Proteolytic fragments of plasminogen were produced to provide AP-binding ligands
- the fragments were prepared as described by Sottrup Jensen, Claeys, Zajdel, Petersen and Magnusson, Progress in Chemical Fibrinolysis and Thrombolysis, 3 191- 209, 1978 Plasminogen fragments were attached to agarose supports as described by Wiman, Biochemistry J.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002313405A CA2313405A1 (en) | 1997-12-09 | 1998-12-09 | Fibrinolytic inhibitor for sealant |
AU18089/99A AU1808999A (en) | 1997-12-09 | 1998-12-09 | Fibrinolytic inhibitor for sealant |
JP2000524007A JP2001525373A (en) | 1997-12-09 | 1998-12-09 | Fibrinolysis inhibitors for sealants |
EP98962967A EP1037659A4 (en) | 1997-12-09 | 1998-12-09 | Fibrinolytic inhibitor for sealant |
NO20002938A NO20002938L (en) | 1997-12-09 | 2000-06-08 | Fibrinolytic inhibitor as a sealant |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6965297P | 1997-12-09 | 1997-12-09 | |
US60/069,652 | 1997-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999029338A1 true WO1999029338A1 (en) | 1999-06-17 |
Family
ID=22090369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/026059 WO1999029338A1 (en) | 1997-12-09 | 1998-12-09 | Fibrinolytic inhibitor for sealant |
Country Status (7)
Country | Link |
---|---|
US (1) | US6492494B1 (en) |
EP (1) | EP1037659A4 (en) |
JP (1) | JP2001525373A (en) |
AU (1) | AU1808999A (en) |
CA (1) | CA2313405A1 (en) |
NO (1) | NO20002938L (en) |
WO (1) | WO1999029338A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1157706A2 (en) * | 2000-05-22 | 2001-11-28 | Aventis Behring GmbH | Use of a fibrinogen-containing tissue glue for the prevention of tissue adhesions |
WO2002089868A1 (en) * | 2001-05-09 | 2002-11-14 | Baxter International Inc. | Fibrin material and method for producing and using the same |
WO2003039587A1 (en) * | 2001-11-09 | 2003-05-15 | Novo Nordisk Health Care Ag | Pharmaceutical composition comprising factor vii polypeptides and protein s inhibitors |
US6599515B1 (en) | 1995-01-16 | 2003-07-29 | Baxter International Inc. | Fibrin porous structure |
WO2004073760A1 (en) * | 2003-02-20 | 2004-09-02 | Hamilton Civic Hospitals Research Development Inc. | Coating composition for polymeric surfaces comprising serpin or serpin derivatives |
US6965014B1 (en) | 1996-01-16 | 2005-11-15 | Baxter International Inc. | Fibrin material and method for producing and using the same |
EP1695724A1 (en) * | 2001-05-09 | 2006-08-30 | Baxter International Inc. | Fibrin material and method for producing and using the same |
US7276235B2 (en) | 1998-11-18 | 2007-10-02 | Zlb Behring Gmbh | Tissue glue with improved antiadhesive properties |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070042015A1 (en) * | 2003-02-20 | 2007-02-22 | Berry Leslie R | Coating composition for polymeric surfaces comprising serpin or serpin derivatives |
DE102005003145B4 (en) * | 2005-01-21 | 2006-10-19 | Dade Behring Marburg Gmbh | Stablies, chromogenic liquid reagent and its use in coagulation diagnostic tests |
US9119901B2 (en) | 2005-04-28 | 2015-09-01 | Warsaw Orthopedic, Inc. | Surface treatments for promoting selective tissue attachment to medical impants |
US8414907B2 (en) | 2005-04-28 | 2013-04-09 | Warsaw Orthopedic, Inc. | Coatings on medical implants to guide soft tissue healing |
WO2010129258A2 (en) | 2009-04-27 | 2010-11-11 | Mallinckrodt Inc. | Tissue sealant compositions, vascular closure devices, and uses thereof |
US20130202675A1 (en) | 2012-02-03 | 2013-08-08 | Dynasil Biomedical Corporation | Systems and methods for the fabrication of tissue patches |
US9833538B2 (en) | 2015-08-07 | 2017-12-05 | Xcede Technologies, Inc. | Adhesive compositions and related methods |
US10588998B2 (en) | 2015-08-07 | 2020-03-17 | Xcede Technologies, Inc. | Adhesive compositions and related methods |
US9540548B1 (en) | 2015-08-07 | 2017-01-10 | Xcede Technologies, Inc. | Adhesive compositions and related methods |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0592242A1 (en) * | 1992-10-08 | 1994-04-13 | E.R. Squibb & Sons, Inc. | Fibrin sealant compositions and method for utilizing same |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4442655A (en) * | 1981-06-25 | 1984-04-17 | Serapharm Michael Stroetmann | Fibrinogen-containing dry preparation, manufacture and use thereof |
DE3175003D1 (en) * | 1981-06-25 | 1986-08-28 | Serapharm Gmbh & Co Kg | Enriched plasma derivative for promoting wound sealing and wound healing |
US5226877A (en) * | 1989-06-23 | 1993-07-13 | Epstein Gordon H | Method and apparatus for preparing fibrinogen adhesive from whole blood |
US5464471A (en) * | 1994-11-10 | 1995-11-07 | Whalen Biomedical Inc. | Fibrin monomer based tissue adhesive |
CA2206516C (en) * | 1994-12-02 | 2007-04-17 | Bristol-Myers Squibb Company | Centrifuge reagent delivery system |
NZ325580A (en) * | 1995-12-07 | 2000-03-27 | Bristol Myers Squibb Co | A device for applying a mixture of two liquid components through a nozzle having outlets in a straight line |
-
1998
- 1998-12-09 JP JP2000524007A patent/JP2001525373A/en active Pending
- 1998-12-09 US US09/208,352 patent/US6492494B1/en not_active Expired - Fee Related
- 1998-12-09 CA CA002313405A patent/CA2313405A1/en not_active Abandoned
- 1998-12-09 AU AU18089/99A patent/AU1808999A/en not_active Abandoned
- 1998-12-09 EP EP98962967A patent/EP1037659A4/en not_active Withdrawn
- 1998-12-09 WO PCT/US1998/026059 patent/WO1999029338A1/en active Application Filing
-
2000
- 2000-06-08 NO NO20002938A patent/NO20002938L/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0592242A1 (en) * | 1992-10-08 | 1994-04-13 | E.R. Squibb & Sons, Inc. | Fibrin sealant compositions and method for utilizing same |
Non-Patent Citations (3)
Title |
---|
LEE S C, ET AL.: "PURIFICATION OF HUMAN ALPHA-ANTIPLASMIN WITH CHICKEN IGY SPECIFIC TO ITS CARBOXY-TERMINAL PEPTIDE", PREPARATIVE BIOCHEMISTRY, NEW YORK, NY, US, vol. 27, no. 04, 1 January 1997 (1997-01-01), US, pages 227 - 237, XP002918319 * |
See also references of EP1037659A4 * |
WIMAN B: "AFINITY-CHROMATOGRAPHIC PURIFICATION OF HUMAN ALPHA2-ANTIPLASMIN", BIOCHEMICAL JOURNAL, PORTLAND PRESS LTD., GB, vol. 191, no. 01, 1 January 1980 (1980-01-01), GB, pages 229 - 232, XP002918320, ISSN: 0264-6021 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6599515B1 (en) | 1995-01-16 | 2003-07-29 | Baxter International Inc. | Fibrin porous structure |
US6965014B1 (en) | 1996-01-16 | 2005-11-15 | Baxter International Inc. | Fibrin material and method for producing and using the same |
US7276235B2 (en) | 1998-11-18 | 2007-10-02 | Zlb Behring Gmbh | Tissue glue with improved antiadhesive properties |
EP1157706A2 (en) * | 2000-05-22 | 2001-11-28 | Aventis Behring GmbH | Use of a fibrinogen-containing tissue glue for the prevention of tissue adhesions |
EP1157706A3 (en) * | 2000-05-22 | 2002-03-06 | Aventis Behring GmbH | Use of a fibrinogen-containing tissue glue for the prevention of tissue adhesions |
EP1837039A2 (en) * | 2000-05-22 | 2007-09-26 | CSL Behring GmbH | Cloth adhesive with improved anti-adhesive properties |
KR100858226B1 (en) * | 2000-05-22 | 2008-09-12 | 체에스엘 베링 게엠베하 | Tissue glue with improved antiadhesive properties |
EP1837039A3 (en) * | 2000-05-22 | 2011-07-20 | CSL Behring GmbH | Cloth adhesive with improved anti-adhesive properties |
WO2002089868A1 (en) * | 2001-05-09 | 2002-11-14 | Baxter International Inc. | Fibrin material and method for producing and using the same |
EP1695724A1 (en) * | 2001-05-09 | 2006-08-30 | Baxter International Inc. | Fibrin material and method for producing and using the same |
WO2003039587A1 (en) * | 2001-11-09 | 2003-05-15 | Novo Nordisk Health Care Ag | Pharmaceutical composition comprising factor vii polypeptides and protein s inhibitors |
WO2004073760A1 (en) * | 2003-02-20 | 2004-09-02 | Hamilton Civic Hospitals Research Development Inc. | Coating composition for polymeric surfaces comprising serpin or serpin derivatives |
Also Published As
Publication number | Publication date |
---|---|
JP2001525373A (en) | 2001-12-11 |
US6492494B1 (en) | 2002-12-10 |
EP1037659A4 (en) | 2005-02-09 |
NO20002938L (en) | 2000-08-08 |
AU1808999A (en) | 1999-06-28 |
EP1037659A1 (en) | 2000-09-27 |
CA2313405A1 (en) | 1999-06-17 |
NO20002938D0 (en) | 2000-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6492494B1 (en) | Method of making a fibrin sealant comprising alpha-2-antiplasmin | |
JP3771284B2 (en) | Fibrin sealing composition and method of use | |
KR101195777B1 (en) | Fibrinogen purification | |
US20070219352A1 (en) | Fibrinogen from transgenic animals | |
US6740736B2 (en) | Purification of fibrinogen from milk by use of cation exchange chromatography | |
Hörmann | Interaction with fibrinogen and fibrin | |
JP2001526027A (en) | Fibrinogen converting enzyme hybrid | |
WO1995017907A1 (en) | Methods and compositions for inhibiting thrombogenesis | |
WO2000077227A1 (en) | Fibrin sealant as a transfection/transformation vehicle for gene therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA IL JP MX NO NZ UA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2313405 Country of ref document: CA Ref country code: CA Ref document number: 2313405 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 524007 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998962967 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998962967 Country of ref document: EP |